[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"auto-immune-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:auto-immune-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100603099","early-phase-1-gt719-injection-for-moderate-to-severe-refractory-autoimmune-disease-100603099",false,"NCT07132112","GT719 Injection for Moderate to Severe Refractory Autoimmune Disease","A Single-arm, Open-label Clinical Study of GT719 Injection for Moderate to Severe Refractory Autoimmune Disease","Inclusion Criteria:\n\n* 1\\. Voluntarily enrolled in the study, signed an informed consent form, willing and able to comply with the study protocol.\n* 2\\. Aged 18 to 65 years (inclusive), regardless of gender.\n\nSpecific inclusion criteria:\n\n* 3\\. Participants with systemic lupus erythematosus (SLE)\n\n  1. Meets the classification criteria for SLE in the 2019 European League Against Rheumatism\u002FAmerican College of Rheumatology (EULAR\u002FACR);\n  2. Disease activity score SLEDAI-2000 ≥ 6, with at least one British Islet Lupus Assessment Group Index (BILAG-2004) Grade A (severe manifestations) or two Grade B (moderate manifestations) organ scores, or both; Or the disease activity score SLEDAI-2000 ≥ 8;\n* 4\\. Participants with idiopathic inflammatory myopathy （IIM）\n\n  1. Complies with the 2017 EULAR\u002FACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM)\n  2. Myositis antibody positive;\n  3. . Meets the definition of recurrence, refractory or progressive;\n* 5\\. Participants with systemic sclerosis\n\n  1. . Meet the 2013 American College of Rheumatology (ACR) SSc criteria;\n  2. . SSc related antibodies are positive;\n  3. . Meets the definition of refractory or progressive recurrence\n\nExclusion Criteria:\n\n* 1\\. Within 3 weeks prior to lymphodepleting chemotherapy, complement inhibition therapy (such as Ecuzumab) has been used;\n* 2\\. Received attenuated live vaccine within 4 weeks before lymphodepleting chemotherapy;\n* 3\\. Having undergone major surgery within the 8 weeks prior to screening, or planning to undergo surgery during the study period;\n* 4\\. Medical history of organ transplantation;\n* 5\\. Previously received CAR-T product therapy targeting any target (excluding GT719 therapy);\n* 6\\. According to the investigator's judgment, the situations that hinder participants from participating in the entire trial, confound the trial results, or participate in the trial that are not in the best interests of the participants.","ALL","18 Years","65 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This study is a prospective single-arm open-label clinical trial, including dose escalation and expansion phase, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune disease. A total of 30 subjects will be enrolled in this study.",[27],"Auto Immune Disease","RECRUITING","2026-04-13",{"date":31,"type":32},"2026-04-16","ACTUAL",{"date":34,"type":32},"2025-10-28",{"date":36,"type":21},"2028-08",{"name":38,"class":39},"Grit Biotechnology","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":40},"100619702","phase-1-a-study-of-gr1803-in-systemic-lupus-erythematosus-100619702","NCT07348055","A Study of GR1803 in Systemic Lupus Erythematosus","A Phase Ib\u002FIIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus","Inclusion Criteria:\n\n* comfirmed diagnosis of systemic lupus erythematosus\n* SLEDAI-2K≥6分\n* written informed consent and ability to comply with protocol requirements\n* have received adequate dose of glucocorticoids, antimalarials, immunosuppressants for 3 months\n\nExclusion Criteria:\n\n* with unstable acute and chronic diseases\n* active infection\n* history of malignant tumor within 5 years","60 Years",{"count":50,"type":21},44,[52,53],"PHASE1","PHASE2","to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus",[56,27],"Systemic Lupus Erthematosus",[58,59],"BCMA\u002FCD3 Bispecific Antibody","systemic lupus erythematosus","2026-03-09",{"date":62,"type":32},"2026-03-10",{"date":64,"type":32},"2026-02-02",{"date":66,"type":21},"2027-12-01",{"name":68,"class":39},"Genrix (Shanghai) Biopharmaceutical Co., Ltd.",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100628032","autoimmune-neurological-diseases-and-those-secondary-to-immunotherapy-study-of-immunological-mechanisms-and-research-into-targets-of-immune-attack-100628032","NCT07456358","Autoimmune Neurological Diseases and Those Secondary to Immunotherapy: Study of Immunological Mechanisms and Research Into Targets of Immune Attack","Maladies Neurologiques Auto-immunes et Secondaires à l'immunothérapie : étude Des mécanismes Immunologiques et Recherche Des Cibles de l'Attaque Immune","DINAMIC","Inclusion Criteria:\n\n* Adult patient (aged ≥ 18 years)\n* Affiliated with a social security scheme\n* Express consent to participate in the study\n* Indication for lumbar puncture And\n* Patients with cancer, undergoing treatment with ICIs, presenting neurological symptoms after starting treatment with ICIs. These symptoms must have appeared no more than 3 months after the last administration of ICIs.\n\nOr\n\n* Patients with an autoimmune disease of the central nervous system (diagnosis made by teams 1, 2 and 3) according to internationally recognised criteria, with no history of active cancer in the last 3 years and no other autoimmune disease Or\n* Patients with normal pressure hydrocephalus (NPH) or idiopathic intracranial hypertension (diagnosed based on imaging (brain MRI) and clinical findings), with no history of active cancer in the last 3 years and no active autoimmune disease\n\nExclusion Criteria:\n\n* Contraindication or refusal to perform a lumbar puncture\n* Sample not suitable for research (volume of CSF collected for treatment \\>5 mL)\n* Corticosteroid therapy or other immunomodulatory treatment in progress (discontinued less than 15 days prior to inclusion)\n* Pregnant or breastfeeding women\n* Not affiliated with the social security system, patients under French State Medical Aid for undocumented migrants\n* Patients under guardianship or curatorship, under judicial protection measures, or deprived of their liberty by judicial or administrative decision",true,{"count":79,"type":21},160,[81],"NA","The pathophysiology of neurological toxicities secondary to immune checkpoint inhibitors (ICIs) is unknown. Various mechanisms have been proposed: activation of cytotoxic CD8 T cells, autoantibodies via activation of B cells and CD4 cells, non-specific inflammation through the production of pro-inflammatory cytokines, and complement activation.\n\nThe aim of this research is to characterise the pathophysiological mechanisms of neurotoxicities in cancer patients treated with ICIs.",[84,27],"Neurological Diseases",[86,87,88,89],"Autoimmune neurological diseases","Immunotherapy","Neurotoxocities","Immune checkpoint inhibitors","NOT_YET_RECRUITING","2026-03-04",{"date":93,"type":32},"2026-03-06",{"date":95,"type":21},"2026-03-01",{"date":97,"type":21},"2030-11-01",{"name":99,"class":100},"Assistance Publique - Hôpitaux de Paris","OTHER"]